Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with ...

The appointment of Dr. Jack Moore as Senior Vice President, Clinical Development brings extensive experience in CNS drug development, which could enhance the company’s initiatives for simufilam and ...

Cassava Sciences, Inc. has announced the expected release of topline data from its Phase 3 REFOCUS-ALZ study on simufilam for mild-to-moderate Alzheimer's disease, anticipated in late Q1 or early Q2 ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to ...

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to ...

Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the ...

Cassava Sciences stock hits the lowest value since January 2021 last week, dropping 35% after key scientific advisor Dr. Hoau-Yan Wang was indicted for alleged fraud. Cassava's Phase 3 clinical trials ...

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to ...